SCHEMBL16741925

SCHEMBL16741925

COC(=O)c1ccc2c(ccn2CCN(C)C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.54
HTR2C P28335 3/20 0.54
HTR6 P50406 3/20 0.47
KDM4E B2RXH2 3/20 0.47
ALDH1A1 P00352 3/20 0.47
HPGD P15428 3/20 0.47
HSD17B10 Q99714 2/20 0.47
POLB P06746 1/20 0.47
APOBEC3A P31941 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
APOBEC3G Q9HC16 1/20 0.47
HDAC8 Q9BY41 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
HDAC11 Q96DB2 1/20 0.46
MTNR1A P48039 1/20 0.45
MTNR1B P49286 1/20 0.45
EPHX2 P34913 1/20 0.45
BPTF Q12830 1/20 0.45
TUBB4A P04350 2/20 0.44
TUBB P07437 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30527841 1.00 HTR2A (0.54) HTR2AHTR2CHTR6KDM4EALDH1A1
SCHEMBL18960579 0.86 HTR2C (0.56) HTR2AHTR2CHTR6EPHX2BPTF
SCHEMBL6752488 0.85 HTR2C (0.55) HTR2AHTR2CHTR6ALDH1A1POLB
SCHEMBL29050262 0.84 HTR2C (0.54) HTR2AHTR2CHTR6ALDH1A1POLB
Lithium SCHEMBL30527867 0.84 HTR2C (0.54) HTR2AHTR2CHTR6ALDH1A1POLB
SCHEMBL1809488 0.84 HDAC6 (0.51) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL3349233 0.83 PLG (0.51) KDM4EALDH1A1HPGDHSD17B10POLB
Lithium Ion SCHEMBL27175191 0.83 HTR2C (0.52) HTR2AHTR2CHTR6EPHX2BPTF
SCHEMBL2324058 0.82 TUBB4A (0.62) KDM4EALDH1A1HPGDHSD17B10POLB
SCHEMBL13699049 0.82 KDM4E (0.55) KDM4EALDH1A1HPGDHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12534474-B2 Dihydrofuropyridine derivatives as rho-kinase inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2026-01-27 US disclosed
EP-4263546-B1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARM SPA (IT) 2025-07-02 EP disclosed
US-20240092792-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-03-21 US disclosed
CN-116568303-A Dihydrofuranopyridine derivatives as RHO-kinase inhibitors 奇斯药制品公司 2023-08-08 CN disclosed
US-20170166555-A1 FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS NOVOGEN LIMITED (AU) 2017-06-15 US disclosed
US-20170166555-A1 FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS NOVOGEN LIMITED (AU) 2017-06-15 US disclosed
EP-3074378-A1 FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS Novogen Ltd. (AU) 2016-10-05 EP disclosed
WO-2015074123-A1 FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS Novogen ltd (AU) 2015-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092792-A1 DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS ROCK1, ROCK2, RHOA HTR2A 3783/4885HTR2C 3583/4885HTR6 3115/4885
US-20170166555-A1 FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS TPM3, TPM4, TNNI3 HTR2A 1880/4885HTR2C 1642/4885HTR6 980/4885
US-12534474-B2 Dihydrofuropyridine derivatives as rho-kinase inhibitors ROCK1, RHOC, ROCK2 HTR2A 3943/4885HTR2C 2103/4885HTR6 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.